🧬 New interim data suggest SKY-0515 may have disease-modifying potential in Huntington disease The investigational oral therapy achieved up to 69% lowering of mutant huntingtin protein and showed favorable clinical trends through 12 months 🔗 Read more: www.neurologylive.com/view/sky-051... #HD

👀 Taking a look back at #StrokeAwarenessMonth, emerging research is highlighting how cardiovascular rehabilitation may improve recovery 📊 Data suggest gains in function, fewer readmissions, and lower mortality with structured programs ❤️‍🩹 Read more 👉 www.neurologylive.com/view/stroke-... #Neurology

📊 Real-world NMOSD registry data showed C5 inhibitors eculizumab and ravulizumab reduced ARR from 0.50 to 0.02, with just 5.4% of patients relapsing and no meningococcal infections reported 🧠 Read more here: www.neurologylive.com/view/real-wo... #CMSC2026 #NMOSD #Neurology #BrainHealth #Conference

The #CMSC2026 annual meeting marks the 40th gathering❗ Dating back to 1986, CMSC has remained at the forefront of fostering clinical collaboration, driving innovation in the MS field, and educating the future of neurology specialists View our coverage here: www.neurologylive.com/conferences/...

🧠 Phase 4 DIRECTION data showed Dysport demonstrated comparable safety to Botox in upper limb spasticity, while offering a modestly longer duration of response (14.2 vs 13.8 wks). Could improved durability reduce breakthrough symptoms? Read more 👉 www.neurologylive.com/view/dysport... #Neurology

🧠🚨 @US_FDA grants #PriorityReview to #Bayer ’s investigational FXIa inhibitor #asundexian for secondary stroke prevention after non-cardioembolic ischemic stroke/TIA Phase 3️⃣ data showed reduced recurrent stroke risk without increased major bleeding 📉💊 Read 👉 www.neurologylive.com/view/fda-gra...

🧠 #StrokeAwarenessMonth shines a light on recovery beyond the acute phase Andrew Abdou, DO, discusses emerging therapies, from neuromodulation to vagus nerve stimulation, that may help #stroke survivors continue making gains years later Read more: www.neurologylive.com/view/stroke-... #Neurology

🆕 study highlights the heterogeneity of #SleepApnea 💤 Researchers identified distinct endotypic traits, such as high arousal threshold & loop gain, linked to excessive daytime sleepiness, paving the way for personalized risk stratification 📊 Read more: www.neurologylive.com/view/study-i... #EDS

⚡ Experts are highlighting how advanced neuroimaging is reshaping stroke intervention decisions Vascular neurologist Firas Bounni, MD, discusses thrombectomy and the future of personalized stroke care 🩻 🩺 Read more: www.neurologylive.com/view/stroke-... #Stroke #Neurology #BrainHealth #AANAM

🧠 🆕 long-term data suggest responsive neurostimulation (RNS) may provide durable seizure reduction in drug-resistant focal epilepsy. ⚡82% median seizure reduction at 3 years ⚡66% achieved ≥50% reduction ⚡>40% achieved ≥90% reduction Read 👉 www.neurologylive.com/view/neurost... #Epilepsy #Neurology

🧬 New findings suggest ~13% of study participants carry a PD–associated genetic variant Researchers also discussed how blood collection may expand access, improve diversity in enrollment, and accelerate neurologic research. Read more: www.neurologylive.com/view/expandi... #Neurology #BrainHealth

📚 How has virtual interviewing changed neurology recruitment? In a new piece, William Kilgo, MD, discusses the modern Match landscape, signaling, and the challenges programs now face in identifying genuine applicant interest. #Neurology #Match2026 Read now: www.neurologylive.com/view/takeawa...

📱 Can smartphone-based monitoring improve care in #PD and dementia? At #AAN2026, Kinan Muhammed of Kneu Health discussed how digital tools may help clinicians remotely track motor + cognitive changes and enable more proactive care Read now: www.neurologylive.com/view/explori... #Neurology #AANAM

🧠 How is deep brain stimulation evolving in #PD care? Rebecca Wilkins discusses newer DBS technologies, patient selection, remote programming, and how DBS may fit alongside emerging PD therapies. ⚡ Read now: www.neurologylive.com/view/how-dee... #DBS #Neurology #Parkinson #Neurotech #BrainHealth

🧠 Could speech become the next major biomarker in rare neurologic disease research? Adam Vogel discusses how speech analytics may provide objective, scalable insight into neurodegeneration in H-ABC and beyond 🗣️ Read more: www.neurologylive.com/view/leverag... #Neurology #RareDisease #Biomarkers

Bill Nye weighs in on the future of rare disease care, genetic testing, and awareness of Friedreich ataxia 🧬 “We want to raise awareness… and get people diagnosed earlier,” Nye notes. Read more: www.neurologylive.com/view/bill-ny... #Neurology #Genetics #AAN2026 #FA #AANAM

🆕 data from a large Danish cohort (~50,000 patients) show a 5x higher cancer risk within 1 yr., with the strongest signal for brain tumors Risk 📉 over time but remains elevated, raising questions about evaluation after unexplained #seizures Read more: www.neurologylive.com/view/first-t... #Neuro

🧠🍽️ For patients with #MyastheniaGravis, fatigue + swallowing issues can make even eating a challenge. A 🆕 national program is delivering ready-made meals to help reduce that burden. 📌 Addressing daily needs is key to improving quality of life. 🔗 👉 www.neurologylive.com/view/new-nat... #Neurology

🧠🚨 Phase 3 METEOROID: Satralizumab ↓ relapse risk by 68% in MOGAD As Michael Levy, MD, PhD, explains—early effect, sustained control, no new safety signals. Read more here: www.neurologylive.com/view/phase-3... #MOGAD #Neurology #AAN2026 #AANAM

🧠🤖 #MachineLearning in neurology won’t succeed on accuracy alone As Tom Fuchs, MD, PHD, notes, tools must be fast, transparent, and built for real workflows. 📌 The future of AI = usable #AI. 🔗 👉 www.neurologylive.com/view/what-ca... #Neurology #AI #DigitalHealth

🧠💬 “Durability” is the keyword. In NeuroVoices, Hubert Fernandez breaks down TEMPO-4 and how tavapadon could reshape long-term Parkinson disease management—especially around delaying levodopa. 🔗 👇 www.neurologylive.com/view/neurovo... #Parkinsons #Neurology

💜 During #Parkinson Disease Awareness Month, new insights highlight how PD differs in women: ⚖️ Hormonal shifts may shape risk & symptoms ⚡ ↑ dyskinesia, anxiety, fatigue 📉 Trial underrepresentation limits guidance 🏡 Added caregiving burden 🔗 👉 www.neurologylive.com/view/sex-dif... #Neurology

🧠📊 Phase 3 data at the 2026 #AANAM show IVIG improved response rates in autoimmune encephalitis refractory to steroids: ⚡ 57.1% vs 0% (antibody+) ⚡ 50% vs 25% overall ⚡ Functional gains by Week 4 Read more now 👇 www.neurologylive.com/view/ivig-de... #Neurology #Neuroimmunology #BrainHealth #Phase3

What a great time at #AANAM 2026! I saw old and new friends, hung out with the amazing @ndecinstitute.bsky.social crew, met Bill Nye the Science guy and gave talks on #mentorship #timemanagement and #leadership. @aanmember.bsky.social

Our time is limited more than ever. Thanks for joining my discussion on practical strategies for aligning tasks with values, protecting deep work, managing the inbox, & creating space for a more meaningful professional life at the #AANAM. #MedEd #TimeManagement #AcademicMedicine

🧠 🆕 insomnia data at the 2026 #AANAM Investigational OX2R antagonist HS-10506 showed dose-dependent reductions in sleep latency with broader improvements in sleep outcomes and favorable tolerability. A potential next-gen approach to sleep therapy 👇 www.neurologylive.com/view/phase-1... #Neurology

Reducing dyskinesia in advanced #PD 🧠 🆕 phase 3 post hoc data show foslevodopa foscarbidopa led to elimination of troublesome dyskinesia in many patients 📉 A meaningful step toward improving daily function 💪 More from #AAN2026 👇 www.neurologylive.com/view/phase-3... #Parkinson #Neurology #AANAM

Excited for my first #AANAM! Come chat at my posters Sunday! P1 8-9am: morphometric differences from typical development after left but not right pediatric resection P2 11:45am-12:45pm: characterization/prediction of functional outcomes after pediatric hemispheric surgery @aanmember.bsky.social

#AANAM Day 2 wrap up! Tim Miller received the Potamkin Prize; Eric Landsness won the Sleep Medicine Investigator Award, and Yan Wang won the Stroke Leadership Prize! Presenters: Suzanne Schindler, Eric McDade, Beau Ances and Jorge Llibre-Guerra, Eva Klinman (poster)

Dr. Tracy Milligan from NYMC receiving the A.B. Baker Award for Lifetime Achievement in Neurologic Education and delivering her Keynote Address, “The Neurology Family Tree and Helping Others Thrive,” at the @aanmember.bsky.social #AANAM speaking to the power of mentorship from childhood onwards: 🧠 🦉

Fantastic start to #AANAM at the Controversies in Neurology Plenary

A novel mechanism enters the spotlight in gMG 🌍📊 Telitacicept is now being evaluated in a global #Phase3 trial—targeting both BAFF & APRIL to reduce autoantibody production 🔬 More from #AANAM 👇 www.neurologylive.com/view/telitac... #Neurology #ClinicalTrials #gMG #BrainHealth

The 2026 #AANAM has begun—and NeurologyLive is covering it all❗ 🧠 From late-breaking data to expert perspectives, we’ve got you covered. Follow along to with all our coverage here: www.neurologylive.com/conferences/... #Neurology #AnnualMeeting #AmericanAcademyNeurology #BrainHealth #Neuro

Wakefulness without compromise? 👀 New phase 3️⃣ data suggest solriamfetol improves daytime sleepiness in #OSA—without meaningful disruption to nighttime sleep. A key consideration for clinicians balancing EDS treatment and sleep quality. Read more 👇 www.neurologylive.com/view/solriam... #Neurology

Brain injury care doesn’t stop at discharge 🧠 In this Q&A, Erika Trovato, DO, MS, highlights: 🔹 Interdisciplinary rehab 🔹 Emerging tech like neuromodulation 🔹 The importance of long-term + caregiver support Read more 👉 www.neurologylive.com/view/advanci... #Neurology #TBI #Rehab #BrainHealth

🧠 April is #MOGAD Awareness Month Once misclassified as MS or NMOSD, MOGAD is now recognized as a distinct neuroimmunologic disease—thanks in part to advances in cell-based antibody assays 🔬 Awareness = better diagnosis + better care Read more here: www.neurologylive.com/view/mogad-a... #Neurology

🏆 And your #NeuroMadness Champion is… #1 Natalizumab 🎉 After weeks of matchups, debates, and votes, one rose above the rest to snag the crown 👑 A true game-changer in neurology— big thanks to everyone who followed along and voted! Until next year! #Neurology #MarchMadness #MedTwitter #March

What if consciousness isn’t always visible at the bedside? 👀 🎙️ Jennifer Frontera, MD, and Brian Edlow, MD, explore covert consciousness, advanced EEG/fMRI, and what it means for ICU decision-making 🧠 A must-listen for clinicians ⏱️ Part-1: 26 min 🔗 👉 www.neurologylive.com/view/frontli... #Neurology

📊 Researchers found Modafinil significantly improves both objective and subjective sleepiness measures in #Narcolepsy 🧠 5 RCTs | 997 patients ⚡ Longer wakefulness on MWT 📉 Lower #ESS scores These findings highlight a gap in randomized trials More ➡️ www.neurologylive.com/view/updated... #Neurology

🧠 Miss any FDA neurology approvals in Q1? NeurologyLive® rounded up key regulatory decisions from Q1 clinicians should know, from the first pediatric Menkes disease therapy to a higher-dose regimen of Nusinersen. See the full recap 👇 www.neurologylive.com/view/q1-2026... #Neurology #FDA #MS

👀 In case you missed it… NeurologyLive® hosted a roundtable exploring the 2026 acute ischemic stroke guidelines with Andrei Alexandrov, MD, and Beth Cavanaugh, MD who break down what these updates mean for #StrokeCare Watch the discussion 🎥 www.neurologylive.com/roundtable-d... #Stroke #Neurology

🧠 Could high-intensity inpatient rehabilitation improve outcomes in PD? Steven Markos, MD, discusses a 2-week interdisciplinary rehab program that showed improvements in mobility, daily function, and vocal outcomes for patients with PD Read more: www.neurologylive.com/view/rethink... #Neurology

Our latest Mind Moments dives into the real-world challenges of diagnosing and treating seronegative gMG with Sarah Hoffmann, MD 👉 Why diagnosis isn’t always straightforward 👉 Why some patients need reevaluation 👉 Why trials in this space remain difficult 📲 www.neurologylive.com/view/episode...

🏆 The #NeuroMadness Championship is here! After weeks of polling, only one contender remains from each bracket: #1 Natalizumab Vs. #2 OPERA 1 & 2 (MS) One landmark therapy and one landmark clinical trial face off. Vote now to crown the champion‼️ #Neurology #MarchMadness #March

🧬 New 64-week data from the STEER study highlight the potential durability of one-time gene therapy in #SMA 📈 Key outcomes • +2.75 HFMSE improvement • +2.93 RULM improvement • 🚫 new safety signals Expert insights from Nazem Atassi, MD ⬇️ www.neurologylive.com/view/positio... #Neurology #GeneTherapy

🚨 The votes are IN!🚨 The #NeuroMadness Championship matchup is officially set 🧠🏀 After weeks of fierce competition, only TWO teams remain: #1 Natalizumab will take on #2 OPERA I & II (MS) in the #Finals Stay tuned for the final poll of the tournament 👀 #Neurology #MarchMadness #March #Clinical

🧠 Living with #MS isn’t just about physical symptoms Constance V. Katsafanas, DO, explores why personalized treatment strategies and addressing invisible symptoms are essential for improving patient outcomes Read more: www.neurologylive.com/view/persona... #Neurology #MSAwareness

🧬 Fabry disease update ⬆️ The #EC has approved every-4-week dosing of pegunigalsidase alfa (Elfabrio) for adults with Fabry disease stable on ERT. Rachele Berria, MD, PhD, discusses the clinical implications. Read more here 👉 www.neurologylive.com/view/what-cl... #Neurology #ClinicalTrials

🚨 On to the #FinalFour in #NeuroMadness Drug Classes: #1 Natalizumab defeats #4 Gepants and will face #3 Anti-CGRP mAbs Clinical Trials: #6 SANAD (Epilepsy) upsets #1 AFFIRM (MS) and meets up with #2 OPERA I & II (MS) Only 3 matchups remain so make sure to add your voice by voting! #Neurology

#Breaking: 🚨 The @fda.gov has approved a higher-dose regimen of nusinersen (Spinraza; Biogen) for Spinal Muscular Atrophy. The high-dose regimen is expected to introduce a faster loading schedule for treatment-naïve patients. Read more: www.neurologylive.com/view/fda-app... #Neurology #FDA #SMA